Emerging clinical applications in cardiovascular pharmacogenomics

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 2, 2011, Pages 206-215

  Damani, Samir B ^a   Topo, Eric J ^a  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; HEMATOLOGIC AGENT;

ANIMAL; CARDIOVASCULAR DISEASE; GENETICS; HUMAN; PHARMACOGENETICS; REVIEW;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HEMATOLOGIC AGENTS; HUMANS; PHARMACOGENETICS;

EID: 79957934004     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.113     Document Type: Review

References (65)

1. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, Deluca TM, Verbrugge RR, Burckart GJ, Lesko LJ. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008, 28:992-998.
2. Bhatt DL. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?. JAMA 2009, 302:896-897.
3. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med2009, 150:73-83.
4. Woodcock J, Lesko LJ. Pharmacogenetics-tailoring treatment for the outliers. N Eng J Med2009, 360:811-813.
5. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004, 141:137-147.
6. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007, 297:1551-1561.
7. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008, 322:881-888.
8. Damani SB, Topol EJ. Future use of genomics in coronary artery disease. J Am Coll Cardiol 2007, 50:1933-1940.
9. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
10. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
11. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Eng J Med 2008, 359:789-799.
12. Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009, 41:1345-1349.
13. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
14. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA- B*5701 genotype is a major determinant of drug- induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
15. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
16. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
17. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 2001, 345: 494-502.
18. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percu- taneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
19. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
20. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
21. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Eng J Med 2009, 360:354-362.
22. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Eng J Med2009, 360:363-375.
23. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512-518.
24. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103:5-10.
25. Mehta SR. Current Oasis-7: benefit to doubling clopidogrel dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. Eur Soc Cong 2009.
26. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med2007, 357:2001-2015.
27. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2009, 361:1045-1057.
28. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480-486.
29. Wysowski DK, Nourjah P, Swartz L. Bleeding compli- cations with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167:1414-1419.
30. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001, 119:108S-121S.
31. Moyer TP, O'Kane DJ, Baudhuin LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009, 84:1079-1094.
32. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Eng J Med2005, 352:2285-2293.
33. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Eng J Med2009, 360:753-764.
34. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo warfarin effectiveness study). J Am Coll Cardiol.
35. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
36. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 2003, 107:1100-1102.
37. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
38. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995, 26:1257-1263.
39. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta- blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529-1538.
40. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006, 103:11288-11293.
41. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14:510-517.
42. Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 2003, 63:9-18.
43. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33:447-454.
44. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999, 286:115-143.
45. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002, 155:487-495.
46. Ordovas JM, Schaefer EJ. Genetic determinants of plasma lipid response to dietary intervention: the role of the APOA1/C3/A4 gene cluster and the APOE gene. Br J Nutr 2000, 83:S127-S136.
47. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8:1-21.
48. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41:56-65.
49. Gerdes LU, Gerdes C, Kervinen K, et al. The apolipo- protein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000, 101:1366-1371.
50. Shiffman D, Chasman DI, Zee RY, et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol 2008, 51:444-448.
51. Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008, 51:435-443.
52. Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE ITTIMI 22 study. J Am Coll Cardiol 2008, 51:449-455.
53. Statin Check. Berkely HeartLab Inc.; 2009.
54. Wellcome Trust Case Control Consortium. Genomewide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007, 447:661-678.
55. Hauser ER, Crossman DC, Granger CB, et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD study. Am J Hum Genet 2004, 75:436-47.
56. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316:1491-1493.
57. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40:189-197.
58. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
59. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Eng J Med2007, 357:443-453.
60. Erdmann J, Grosshennig A, Braund PS, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 2009, 41:280-282.
61. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009, 41:334-341.
62. Marian AJ. Surprises of the genome and "personalized" medicine. J Am Coll Cardiol 2008, 51:456-458.
63. Iakoubova O, Shepherd J, Sacks F. Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy. J Am Coll Cardiol 2008, 51:2195-2196.
64. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006, 372:432-443.
65. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.